Siemens’ new Anti-Cyclic Citrullinated Peptide (anti-CCP) IgG assay, a blood test for the diagnosis of Rheumatoid Arthritis (RA), is now available for sale outside the U.S. on IMMULITE® 2000/2000 XPi systems. RA is a disease that affects one percent of the population worldwide.2 High levels of the anti-CCP antibody indicates a more aggressive RA and a higher risk of joint damage as compared to patients with low levels. In the past, the Rheumatoid factor (RF) test along with physical assessment of the patient was used as criteria for RA diagnosis. However, clinicians agreed that these criteria were not sufficient for the diagnosis of early RA. With a specificity of 99 percent, the anti-CCP assay from Siemens is an accurate marker for RA diagnosis and RA differentiation from other arthritic conditions. Anti-CCP antibodies pre-date the diagnosis of RA and may be found years before symptoms of RA develop. Furthermore, the specificity is higher compared to the RF test: 96 to 100 percent compared to 74 to 87 percent respectively. Anti-CCP can also differentiate RA from other inflammatory arthritic conditions.
Not available for sale in the U.S. Product availability varies by country
Yelin E, Callahan LF. The economic cost and social and psychological impact of musculoskeletal conditions. Arthritis Rheum. 1995;38:1351-62.